These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 17200349

  • 1. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
    Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG.
    Clin Cancer Res; 2007 Jan 01; 13(1):144-51. PubMed ID: 17200349
    [Abstract] [Full Text] [Related]

  • 2. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG.
    Ann N Y Acad Sci; 2006 Dec 01; 1091():270-81. PubMed ID: 17341621
    [Abstract] [Full Text] [Related]

  • 3. E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation.
    Endo-Munoz L, Dahler A, Teakle N, Rickwood D, Hazar-Rethinam M, Abdul-Jabbar I, Sommerville S, Dickinson I, Kaur P, Paquet-Fifield S, Saunders N.
    Cancer Res; 2009 Mar 01; 69(5):1800-8. PubMed ID: 19223542
    [Abstract] [Full Text] [Related]

  • 4. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF.
    Clin Cancer Res; 2001 Oct 01; 7(10):2984-97. PubMed ID: 11595686
    [Abstract] [Full Text] [Related]

  • 5. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
    Rakha EA, Pinder SE, Paish EC, Robertson JF, Ellis IO.
    J Pathol; 2004 Jul 01; 203(3):754-61. PubMed ID: 15221934
    [Abstract] [Full Text] [Related]

  • 6. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.
    J Clin Oncol; 2007 Feb 10; 25(5):517-25. PubMed ID: 17290060
    [Abstract] [Full Text] [Related]

  • 7. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.
    Gynecol Oncol; 2009 Aug 10; 114(2):253-9. PubMed ID: 19446316
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF.
    Reimer D, Sadr S, Wiedemair A, Concin N, Hofstetter G, Marth C, Zeimet AG.
    Cancer Biol Ther; 2006 Jul 10; 5(7):771-6. PubMed ID: 16721044
    [Abstract] [Full Text] [Related]

  • 9. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
    De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, van Engeland M, Sieben NL.
    J Pathol; 2009 Jan 10; 217(1):14-20. PubMed ID: 18991331
    [Abstract] [Full Text] [Related]

  • 10. Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus.
    Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, Sugano I, Ishida Y.
    J Clin Pathol; 2005 Sep 10; 58(9):904-10. PubMed ID: 16126868
    [Abstract] [Full Text] [Related]

  • 11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 10; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 12. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA.
    Gynecol Oncol; 2008 Feb 10; 108(2):421-7. PubMed ID: 18036640
    [Abstract] [Full Text] [Related]

  • 13. Prognostic values of E2F mRNA expression in human gastric cancer.
    Manicum T, Ni F, Ye Y, Fan X, Chen BC.
    Biosci Rep; 2018 Dec 21; 38(6):. PubMed ID: 30487158
    [Abstract] [Full Text] [Related]

  • 14. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 15. Expression and prognostic role of E2F transcription factors in high-grade glioma.
    Yu H, Li Z, Wang M.
    CNS Neurosci Ther; 2020 Jul 01; 26(7):741-753. PubMed ID: 32064771
    [Abstract] [Full Text] [Related]

  • 16. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients.
    Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP.
    Clin Cancer Res; 2001 Aug 01; 7(8):2380-6. PubMed ID: 11489816
    [Abstract] [Full Text] [Related]

  • 17. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J, Shih IeM, Salani R, Chan DW, Zhang Z.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
    Chu J, Zhu Y, Liu Y, Sun L, Lv X, Wu Y, Hu P, Su F, Gong C, Song E, Liu B, Liu Q.
    Oncotarget; 2015 Oct 13; 6(31):31944-57. PubMed ID: 26397135
    [Abstract] [Full Text] [Related]

  • 20. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T.
    Anticancer Res; 2008 Oct 13; 28(2A):949-55. PubMed ID: 18507041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.